Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20876452 | 1.00 | STING1 (0.65) | STING1CYP3A4 | |
| SCHEMBL29689031 | 1.00 | STING1 (0.65) | STING1CYP3A4 | |
| SCHEMBL28635492 | 0.92 | STING1 (0.60) | STING1CYP3A4 | |
| SCHEMBL28635494 | 0.92 | STING1 (0.60) | STING1CYP3A4 | |
| SCHEMBL20876331 | 0.91 | STING1 (0.69) | STING1CYP3A4 | |
| SCHEMBL20876327 | 0.91 | STING1 (0.69) | STING1CYP3A4 | |
| SCHEMBL29689158 | 0.91 | STING1 (0.69) | STING1CYP3A4 | |
| SCHEMBL22408404 | 0.91 | STING1 (0.52) | STING1CYP3A4 | |
| SCHEMBL21630071 | 0.91 | STING1 (0.62) | STING1CYP3A4 | |
| SCHEMBL19451489 | 0.91 | STING1 (0.52) | STING1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4007758-B1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | MERSANA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250011339-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | MERSANA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-11939343-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| CN-111417630-B | Modulators of interferon gene stimulating factor (STING) | 葛兰素史克知识产权开发有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-11377440-B2 | Modulators of stimulator of interferon genes (STING) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-07-05 | — | — | US | disclosed |
| EP-4007758-A1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | Mersana Therapeutics, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114585623-A | Bis [ N- ((5-carbamoyl) -1H-benzo [ d ] imidazol-2-yl) pyrazole-5-carboxamide ] derivatives and related compounds as STING (interferon gene stimulator) agonists for the treatment of cancer | 梅尔莎纳医疗公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220064189-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | MERSANA THERAPEUTICS, INC. | 2022-03-03 | — | — | US | disclosed |
| US-11155567-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| WO-2021026009-A1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | MERSANA THERAPEUTICS, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | MERSANA THERAPEUTICS, INC. | 2021-02-04 | — | — | US | disclosed |
| US-20200291001-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| EP-3692034-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019069270-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939343-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | STING1 1/4885CYP3A4 4415/4885 |
| US-20220064189-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | STING1, IRF3, MAVS | STING1 1/4885CYP3A4 4415/4885 |
| US-11155567-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | STING1 1/4885CYP3A4 4415/4885 |
| US-11377440-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, IFNAR1 | STING1 1/4885CYP3A4 3948/4885 |
| US-20250011339-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | STING1, IRF3, MAVS | STING1 1/4885CYP3A4 4415/4885 |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | STING1, IRF3, MAVS | STING1 1/4885CYP3A4 4415/4885 |
| US-20200291001-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, IFNAR1 | STING1 1/4885CYP3A4 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.